Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former generic drug execs Vegesna and Rivers debarred

Executive Summary

FDA permanently debars ex-CEO of American Therapeutics, Inc. Raju Vegesna and former Bolar exec VP Jack Rivers on April 12 from providing services in any capacity to a person with an approved or pending drug application. Vegesna was sentenced in July 1990 to a two year-jail term and a $50,000 fine on one count of racketeering but fled to India. In July 1992, Rivers was sentenced to four years imprisonment and fined $1 mil. for submitting false data to FDA and obstructing the agency's investigation. Former ATI VP-Operations Sanyasi Kalidindi is foregoing a hearing and requesting that his period of debarment begin immediately. An April 6 letter from his attorney says Kalidindi wants to be considered under debarment provisions that allow termination of debarment after a finding that an individual has provided "substantial assistance" in investigations and prosecutions and that allow debarment to be limited to one year. The letter notes that along with his past cooperation, Kalidini "as recently as April 6" was a witness at grand jury hearings in Baltimore.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts